Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK)
· seekingalpha.com
Stoke Therapeutics outlook: Phase 3 Dravet program catalysts, strong cash runway, and upside from partnerships. Click for more on STOK stock.
Since my last report for Stoke Therapeutics ( STOK ) in June 2025, the ticker is up 148%. My argument for buying the stock was three-fold:
Sean Daly writes on ...